Assignee
CHROMA THERAPEUTICS LTD
GB·12 granted patents·13 pending applications·122 citations·filing 1999–2017
Top patents by PatentIndex Score
25 records- 0193US7932246B2Histone deacetylase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2006·Granted Apr 26, 2011·61 cites·6 claims
- 0289US7939666B2Enzyme inhibitorsCHROMA THERAPEUTICS LTD·Filed 2006·Granted May 10, 2011·15 cites·22 claims
- 0387US7973181B2Hydroxamic acid derivatives as inhibitors of HDAC enzymatic activityCHROMA THERAPEUTICS LTD·Filed 2006·Granted Jul 5, 2011·12 cites·21 claims
- 0484US8044211B2P38 MAP kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2007·Granted Oct 25, 2011·11 cites·28 claims
- 0584US8003695B2IKK-beta serine-threonine protein kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2007·Granted Aug 23, 2011·9 cites·11 claims
- 0679US9388136B2Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt, hydrate or solvate thereofCHROMA THERAPEUTICS LTD·Filed 2013·Granted Jul 12, 2016·3 cites·3 claims
- 0777US9133104B2Enzyme inhibitorsCHROMA THERAPEUTICS LTD·Filed 2014·Granted Sep 15, 2015·3 cites·40 claims
- 0873US9896417B2Tert-butyl N-[2-{4-[6-amino-5-(2,4-difluorobenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorophenyl}ethyl]-L-alaninate or a salt,hydrate or solvate thereofCHROMA THERAPEUTICS LTD·Filed 2016·Granted Feb 20, 2018·1 cites·12 claims
- 0967US7074578B2Methods and means of histone methylationCHROMA THERAPEUTICS LTD·Filed 2002·Granted Jul 11, 2006·6 cites·1 claims
- 1060US2015126534A1Enzyme and receptor modulationCHROMA THERAPEUTICS LTD·Filed 2014·Application pending·0 cites
- 1156US2009215800A1Enzyme and Receptor ModulationCHROMA THERAPEUTICS LTD·Filed 2006·Application pending·0 cites
- 1252US2011046210A1Substituted thiopenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2009·Application pending·0 cites
- 1352US2011190306A1Inhibitors of PLKCHROMA THERAPEUTICS LTD·Filed 2009·Application pending·0 cites
- 1449US9604940B22-aminopyrazine derivatives as CSF-1R kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2013·Granted Mar 28, 2017·0 cites·17 claims
- 1549US2010004250A1Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancerCHROMA THERAPEUTICS LTD·Filed 2007·Application pending·0 cites
- 1646US2011039920A1Inhibitors of ikk-beta serine-theronine protein kinaseCHROMA THERAPEUTICS LTD·Filed 2008·Application pending·0 cites
- 1746US2010216802A1Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancerCHROMA THERAPEUTICS LTD·Filed 2007·Application pending·0 cites
- 1846US2010267774A1P38 map kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2007·Application pending·0 cites
- 1946US2006235012A1Carboline and betacarboline derivatives for use as hdac enzyme inhibitorsCHROMA THERAPEUTICS LTD·Filed 2004·Application pending·0 cites
- 2045US2017157118A12-aminopyrazine derivatives as csf-1 r kinase inhibitorsCHROMA THERAPEUTICS LTD·Filed 2017·Application pending·0 cites
- 2141US2009203711A1Inhibitors of P38 Map KinaseCHROMA THERAPEUTICS LTD·Filed 2007·Application pending·0 cites
- 2240US2010010057A1Thiazole derivatives as inhibitors of p13 kinaseCHROMA THERAPEUTICS LTD·Filed 2007·Application pending·0 cites
- 2339US2016193200A1Benzamide derivatives and their use as hsp90 inhibtorsCHROMA THERAPEUTICS LTD·Filed 2016·Application pending·0 cites
- 2426US6747005B1Assays, methods and means for modulating nuclear localizationCHROMA THERAPEUTICS LTD·Filed 1999·Granted Jun 8, 2004·1 cites·6 claims
- 2521US6890709B1Assays, methods and means for modulating e2f activityCHROMA THERAPEUTICS LTD·Filed 1999·Granted May 10, 2005·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when CHROMA THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →